Clinical Research & TrialsRespiratory syncytial virus (RSV) vaccination is now recommended for every U.S. adult age 75 and older and for adults ages 50 to 74 who have a higher risk of severe RSV, according to current Centers for Disease Control and Prevention (CDC) guidance. The recommendation is based on clinical trials and post-licensure evidence showing that vaccination […]
Read the Full Bite →
Infectious DiseaseAs the 2026–2027 respiratory syncytial virus season approaches, parents now have more than one way to protect an infant from severe RSV, but the choices can be confusing. A September 2026 American Academy of Pediatrics policy update keeps the basic first-season strategy intact while expanding the group of high-risk children who should receive protection during […]
Read the Full Bite →
Clinical Research & TrialsNirsevimab is designed to cover an RSV season with one dose. Trials show protection for at least 5 months, with hospitalization protection through 180 days.
Read the Full Bite →
Clinical Research & TrialsBeyfortus dosing changes by weight and RSV season. Here is when nirsevimab is given as 50 mg, 100 mg, or 200 mg and who is eligible.
Read the Full Bite →
Infectious DiseaseNirsevimab and clesrovimab both prevent severe infant RSV disease, but they bind different viral sites, use different dosing schemes, and were not tested head to head.
Read the Full Bite →
Infectious DiseaseMaternal RSV vaccination and nirsevimab both protect infants from severe RSV, but they work differently and their trial efficacy numbers are not directly comparable.
Read the Full Bite →
Infectious DiseaseA summer surge of Cyclospora — a microscopic parasite that rides in on fresh produce — has infected thousands across 31 states, and investigators still can't name the food behind it.
Read the Full Bite →
Infectious DiseaseScripps researchers are testing tirzepatide against long COVID — entirely from participants' homes.
Read the Full Bite →